Los Angeles, September 7, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting […]
Los Angeles, August 17, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting
Los Angeles, June 1, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, May 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, May 11, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, March 22, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, December 9, 2021 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, November 12, 2021 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide
Los Angeles, October 15, 2021 — Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for
Los Angeles, May 25, 2021 —Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for
Your feedback is very important to us. We will get back to you within 48 hours.
13547 Ventura Boulevard,
Suite 363
Sherman Oaks, CA 91423
For inquiries about access to our investigational medical products outside of clinical trials, please visit our Expanded Access Policy.